ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 090,99
-0,78%
Dow Jones
43 461,21
0,08%
DAX
22 425,93
0,73%
Brent Oil
74,46
0,48%
Bitcoin
93 982,52
-2,38%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cyclo Therapeutics Inc (CYTH)

  7. Cyclo Therapeutics Inc (CYTH) Actualités

CYTH

Cyclo Therapeutics (CYTH)

Cyclo Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CYTH
DateHeureSourceTitreSymboleSociété
07/02/202514h05Business WireCyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)NASDAQ:CYTHCyclo Therapeutics Inc
14/01/202514h05Business WireCyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025NASDAQ:CYTHCyclo Therapeutics Inc
11/12/202413h00GlobeNewswire Inc.Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
14/11/202414h05Business WireCyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
07/11/202401h14GlobeNewswire Inc.Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
21/10/202414h00GlobeNewswire Inc.Pacira BioSciences Appoints Shawn Cross as Chief Financial OfficerNASDAQ:CYTHCyclo Therapeutics Inc
05/09/202415h05Business WireCyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)NASDAQ:CYTHCyclo Therapeutics Inc
26/08/202415h37PR Newswire (US)Kuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law FirmNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202415h37Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202415h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202412h50GlobeNewswire Inc.Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger AgreementNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202412h50Business WireRafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger AgreementNASDAQ:CYTHCyclo Therapeutics Inc
20/08/202419h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
15/08/202415h00Business WireCyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
14/08/202423h28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYTHCyclo Therapeutics Inc
29/07/202415h05Business WireCyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent OfficeNASDAQ:CYTHCyclo Therapeutics Inc
25/06/202415h25Business WireCyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024NASDAQ:CYTHCyclo Therapeutics Inc
14/06/202422h01GlobeNewswire Inc.Rafael Holdings Reports Third Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
30/05/202415h00Business WireCyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1NASDAQ:CYTHCyclo Therapeutics Inc
16/05/202414h05Business WireCyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
18/03/202414h05Business WireCyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
14/03/202414h34Business WireCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s DiseaseNASDAQ:CYTHCyclo Therapeutics Inc
13/03/202422h04GlobeNewswire Inc.Rafael Holdings Reports Second Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
04/03/202422h33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
14/02/202420h44Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
29/01/202415h15Business WireCyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark OfficeNASDAQ:CYTHCyclo Therapeutics Inc
29/12/202303h48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
27/12/202322h15Business WireCyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.NASDAQ:CYTHCyclo Therapeutics Inc
18/12/202315h15Business WireCyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1NASDAQ:CYTHCyclo Therapeutics Inc
14/12/202322h01GlobeNewswire Inc.Rafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CYTH

Dernières Valeurs Consultées

USI
USTECH100
US Tech 100
EU
VIV
Vivendi
COIN
ADAUSD
Cardano
FTSE
UKX
FTSE 100
EU
LR
Legrand
COIN
SOLUSD
Solana
COIN
ETHUSD
Ethereum
NYSE
JPM
JP Morgan Chase
COIN
BTCUSD
Bitcoin
EU
CAP
Capgemini
NYSE
MRK
Merck
EU
DG
Vinci
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces